Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Dec;44(12):1321-5.
doi: 10.1038/ng.2468. Epub 2012 Nov 11.

The genetic landscape of mutations in Burkitt lymphoma

Cassandra Love  1 , Zhen Sun, Dereje Jima, Guojie Li, Jenny Zhang, Rodney Miles, Kristy L Richards, Cherie H Dunphy, William W L Choi, Gopesh Srivastava, Patricia L Lugar, David A Rizzieri, Anand S Lagoo, Leon Bernal-Mizrachi, Karen P Mann, Christopher R Flowers, Kikkeri N Naresh, Andrew M Evens, Amy Chadburn, Leo I Gordon, Magdalena B Czader, Javed I Gill, Eric D Hsi, Adrienne Greenough, Andrea B Moffitt, Matthew McKinney, Anjishnu Banerjee, Vladimir Grubor, Shawn Levy, David B Dunson, Sandeep S Dave
Affiliations

The genetic landscape of mutations in Burkitt lymphoma

Cassandra Love et al. Nat Genet. 2012 Dec.

Abstract

Burkitt lymphoma is characterized by deregulation of MYC, but the contribution of other genetic mutations to the disease is largely unknown. Here, we describe the first completely sequenced genome from a Burkitt lymphoma tumor and germline DNA from the same affected individual. We further sequenced the exomes of 59 Burkitt lymphoma tumors and compared them to sequenced exomes from 94 diffuse large B-cell lymphoma (DLBCL) tumors. We identified 70 genes that were recurrently mutated in Burkitt lymphomas, including ID3, GNA13, RET, PIK3R1 and the SWI/SNF genes ARID1A and SMARCA4. Our data implicate a number of genes in cancer for the first time, including CCT6B, SALL3, FTCD and PC. ID3 mutations occurred in 34% of Burkitt lymphomas and not in DLBCLs. We show experimentally that ID3 mutations promote cell cycle progression and proliferation. Our work thus elucidates commonly occurring gene-coding mutations in Burkitt lymphoma and implicates ID3 as a new tumor suppressor gene.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Results from whole-genome sequencing of a Burkitt lymphoma tumor and germline DNA. The Circos diagram summarizes the somatically acquired genetic variants in a Burkitt lymphoma genome. The outermost ring depicts the chromosome ideogram oriented clockwise, p terminus to q terminus. Centromeres are shown in red. The next three rings indicate somatically acquired mutations falling in intergenic regions, potential regulatory regions and the exome, respectively. The black arc connecting chromosomes 8 and 14 signifies a t(8;14) translocation detected in sequencing data.
Figure 2
Figure 2
Exome sequencing in Burkitt lymphoma. (a) The ratio of somatically acquired transitions and transversions for samples with paired normal tissue are shown for all 14 discovery set samples. (b) The heatmap indicates the mutation patterns of the 19 most frequently implicated genes out of the 70 genes mutated in Burkitt lymphoma. Each column represents an affected individual, and each row represents a gene. (c) The bar graph shows the frequency of variants found per gene across all samples, divided into nonsynonymous and synonymous counts. (d) The bar graph shows the frequency of mutations in all 70 genes mutated in Burkitt lymphoma in each case: orange bars represent samples in the discovery set, and blue bars represent samples in the validation set.
Figure 3
Figure 3
Patterns of exonic mutations in Burkitt lymphoma compared to DLBCL. (a) The bar graph shows the proportion of Burkitt lymphoma and DLBCL samples containing a mutation in each gene. (b) The bar graph shows the number of cases that contain a mutation in the given gene in Burkitt lymphoma and DLBCL. (c) The heatmap shows the association between 55 genes found to be recurrently mutated in Burkitt lymphoma and/or DLBCL. Blue denotes negative association between genes, and orange denotes positive association.
Figure 4
Figure 4
Recurrent ID3 mutations in Burkitt lymphomas. (a) Deep sequencing reads identify recurrent mutations affecting the HLH domain of ID3 in Burkitt lymphomas. Each colored line represents an individual somatic mutation or a rare genetic variant. The conservation of the HLH domain across species is also shown. Red asterisks identify the alterations that were functionally validated. (b) The bar graph shows significantly higher expression of genes involved in the G1 to S-phase transition in ID3-mutant Burkitt lymphoma samples compared to those with wild-type ID3 (FDR = 0.026), as determined in gene set enrichment analysis. Error bars, s.d. (c) Heatmap of genes corresponding to the gene set enrichment msigdb-derived list of those involved in the G1 to S-phase transition. Red denotes high relative expression, and green represents low relative expression across samples. (d) Cell cycle analysis of Jijoye cells expressing mutant ID3 proteins compared to control cells overexpressing GFP, where the red histogram denotes cells in G1 phase, orange denotes S phase, and green denotes G2 phase. The x axis shows the relative fluorescence in the PerCP-Cy5.5 channel. (e) The bar graph summarizes cell cycle analysis from an average of all cells expressing ID3 mutants compared to cells overexpressing GFP (P = 0.03, χ2 test). Error bars, s.d. (f) MTT cell proliferation assay performed on Jijoye cells expressing mutant ID3 or control GFP. Absorbance was read 24 h after plating, with higher absorbance indicating more cells and signifying faster proliferation. Error bars, s.d. (g) Cell cycle analysis of BL41 cells expressing wild-type ID3 compared to those expressing GFP control. (h) The bar graph summarizes cell cycle analysis for BL41 cells expressing wild-type ID3 relative to cells expressing GFP control. (i) MTT cell proliferation assay performed on BL41 cells expressing wild-type ID3 or GFP. Error bars, s.d.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

  • Clinicopathologic and prognostic relevance of ARID1A protein loss in colorectal cancer.
    Wei XL, Wang DS, Xi SY, Wu WJ, Chen DL, Zeng ZL, Wang RY, Huang YX, Jin Y, Wang F, Qiu MZ, Luo HY, Zhang DS, Xu RH. Wei XL, et al. World J Gastroenterol. 2014 Dec 28;20(48):18404-12. doi: 10.3748/wjg.v20.i48.18404. World J Gastroenterol. 2014. PMID: 25561809 Free PMC article.
  • The genetic landscape of high-risk neuroblastoma.
    Pugh TJ, Morozova O, Attiyeh EF, Asgharzadeh S, Wei JS, Auclair D, Carter SL, Cibulskis K, Hanna M, Kiezun A, Kim J, Lawrence MS, Lichenstein L, McKenna A, Pedamallu CS, Ramos AH, Shefler E, Sivachenko A, Sougnez C, Stewart C, Ally A, Birol I, Chiu R, Corbett RD, Hirst M, Jackman SD, Kamoh B, Khodabakshi AH, Krzywinski M, Lo A, Moore RA, Mungall KL, Qian J, Tam A, Thiessen N, Zhao Y, Cole KA, Diamond M, Diskin SJ, Mosse YP, Wood AC, Ji L, Sposto R, Badgett T, London WB, Moyer Y, Gastier-Foster JM, Smith MA, Guidry Auvil JM, Gerhard DS, Hogarty MD, Jones SJ, Lander ES, Gabriel SB, Getz G, Seeger RC, Khan J, Marra MA, Meyerson M, Maris JM. Pugh TJ, et al. Nat Genet. 2013 Mar;45(3):279-84. doi: 10.1038/ng.2529. Epub 2013 Jan 20. Nat Genet. 2013. PMID: 23334666 Free PMC article.
  • The diagnostic gray zone between Burkitt lymphoma and diffuse large B-cell lymphoma is also a gray zone of the mutational spectrum.
    Momose S, Weißbach S, Pischimarov J, Nedeva T, Bach E, Rudelius M, Geissinger E, Staiger AM, Ott G, Rosenwald A. Momose S, et al. Leukemia. 2015 Aug;29(8):1789-91. doi: 10.1038/leu.2015.34. Epub 2015 Feb 12. Leukemia. 2015. PMID: 25673238 No abstract available.
  • Distinct Proteomic Profile of Spermatozoa from Men with Seminomatous and Non-Seminomatous Testicular Germ Cell Tumors.
    Panner Selvam MK, Alves MG, Dias TR, Pushparaj PN, Agarwal A. Panner Selvam MK, et al. Int J Mol Sci. 2020 Jul 8;21(14):4817. doi: 10.3390/ijms21144817. Int J Mol Sci. 2020. PMID: 32650378 Free PMC article.
  • PI3K Isoforms in B Cells.
    Deenick EK, Bier J, Lau A. Deenick EK, et al. Curr Top Microbiol Immunol. 2022;436:235-254. doi: 10.1007/978-3-031-06566-8_10. Curr Top Microbiol Immunol. 2022. PMID: 36243847
See all "Cited by" articles

References

    1. Dave SS, et al. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med. 2006;354:2431–2442. - PubMed
    1. Schiffman JD, et al. Genome wide copy number analysis of paediatric Burkitt lymphoma using formalin-fixed tissues reveals a subset with gain of chromosome 13q and corresponding miRNA over expression. Br J Haematol. 2011;155:477–486. - PMC - PubMed
    1. Hummel M, et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profling. N Engl J Med. 2006;354:2419–2430. - PubMed
    1. Swerdlow SH, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th. IARC Press; Lyon, France: 2008.
    1. Krzywinski M, et al. Circos: an information aesthetic for comparative genomics. Genome Res. 2009;19:1639–1645. - PMC - PubMed

Publication types

MeSH terms

Substances

Associated data